- Home
- YHGJ vs CING Comparison
YHGJ vs CING Comparison
Compare YHGJ & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- CING
- Stock Information
- Founded
- YHGJ 1975
- CING 2012
- Country
- YHGJ United States
- CING United States
- Employees
- YHGJ N/A
- CING N/A
- Industry
- YHGJ Specialty Chemicals
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- YHGJ Industrials
- CING Health Care
- Exchange
- YHGJ Nasdaq
- CING Nasdaq
- Market Cap
- YHGJ 25.9M
- CING 23.0M
- IPO Year
- YHGJ 1997
- CING 2021
- Fundamental
- Price
- YHGJ $5.42
- CING $4.00
- Analyst Decision
- YHGJ
- CING Strong Buy
- Analyst Count
- YHGJ 0
- CING 4
- Target Price
- YHGJ N/A
- CING $33.00
- AVG Volume (30 Days)
- YHGJ 401.2K
- CING 195.7K
- Earning Date
- YHGJ 11-07-2025
- CING 11-06-2025
- Dividend Yield
- YHGJ N/A
- CING N/A
- EPS Growth
- YHGJ N/A
- CING N/A
- EPS
- YHGJ N/A
- CING N/A
- Revenue
- YHGJ $18,964,000.00
- CING N/A
- Revenue This Year
- YHGJ N/A
- CING N/A
- Revenue Next Year
- YHGJ N/A
- CING N/A
- P/E Ratio
- YHGJ N/A
- CING N/A
- Revenue Growth
- YHGJ 5.70
- CING N/A
- 52 Week Low
- YHGJ $4.35
- CING $3.02
- 52 Week High
- YHGJ $12.70
- CING $6.01
- Technical
- Relative Strength Index (RSI)
- YHGJ 58.82
- CING 52.26
- Support Level
- YHGJ $5.31
- CING $3.73
- Resistance Level
- YHGJ $10.29
- CING $4.40
- Average True Range (ATR)
- YHGJ 0.95
- CING 0.26
- MACD
- YHGJ 0.07
- CING 0.03
- Stochastic Oscillator
- YHGJ 50.14
- CING 55.41
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.